



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C07C 257/16, 257/14		A1	(11) International Publication Number: WO 99/31051 (43) International Publication Date: 24 June 1999 (24.06.99)
<p>(21) International Application Number: PCT/GB98/03715</p> <p>(22) International Filing Date: 11 December 1998 (11.12.98)</p> <p>(30) Priority Data: 9726388.3 12 December 1997 (12.12.97) GB</p> <p>(71) Applicant (<i>for all designated States except US</i>): CEREBRUS LIMITED [GB/GB]; Oakdene Court, 613 Reading Road, Winnersh, Wokingham RG41 5UA (GB).</p> <p>(72) Inventors; and</p> <p>(75) Inventors/Applicants (<i>for US only</i>): GILLESPIE, Roger, John [GB/GB]; Lilac Cottage, Minety Lane, Oaksey, Malmesbury, Wilts SN16 9SY (GB). SNAPE, Michael, Fredrick [GB/GB]; 10 Uffington Road, West Norwood, London SE27 0RW (GB). WARD, Simon, Edward [GB/GB]; 53 Brighton Road, Reading RG6 1PS (GB).</p> <p>(74) Agent: HOWARD, Paul, Nicholas; Carpmaels & Ransford, 43 Bloomsbury Square, London WC1A 2RA (GB).</p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i></p>	
<p>(54) Title: 1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION</p> <p>(57) Abstract</p> <p>Use of a compound of the formula (1), wherein X is an alkylene chain comprising 0, 1, 2, 3 or 4 carbon atoms; R¹, R² and R³ are independently selected from hydrogen, alkyl and aryl; R⁴, R⁵ and R⁶ are independently selected from hydrogen, alkyl, aryl, halogen and alkoxy; and prodrugs thereof and pharmaceutically acceptable salts thereof; in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.</p> <p style="text-align: right;">(1)</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

1-(ADAMANTYL)AMIDINES AND THEIR USE IN THE TREATMENT OF CONDITIONS GENERALLY ASSOCIATED WITH ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION

The present invention relates to compounds and compositions for use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission.

The excitatory neurotransmission underlying brain function is primarily (about 80 per cent) dependent on the action of glutamate and other related neurotransmitters on specific receptors activated by the excitatory amino acids. These receptors fall into several categories, one of which is the glutamate receptor specifically sensitive to the agonist N-methyl-D-aspartate (the NMDA receptor). NMDA receptor subtypes are ubiquitously expressed in mammalian brain and have unique properties underlying their role in synaptic function and plasticity. In view of the central role of these receptors in normal central nervous system function, numerous suggestions have been made as to the utility of drugs acting at this receptor to modulate the processes underlying various disease states. The NMDA receptor has been studied with particular interest in relation to its apparent involvement in the pathophysiology of neurodegenerative diseases.

Non-competitive antagonists at this receptor should be particularly advantageous in the treatment of diseases since such compounds would have activity that should not be overcome by high levels of endogenous agonists and would act equally well independent of the endogenous agonist activating the receptor. This is important since high levels of endogenous glutamate can occur in certain pathological processes and there are a variety of different endogenous agonists that can act through a variety of specific modulatory agonist binding sites on the receptor.

A number of NMDA antagonists have been disclosed which operate by binding to the ion-channel of the NMDA receptor. The advantage of channel blockers is that they operate only on the "open" channel and therefore do not affect unactivated receptors. In addition they are effective regardless of the mechanism of receptor stimulation and their effect will not be diminished by large concentrations of endogenous agonist.


Given that the NMDA receptor plays a primary role in normal central nervous system function, it is not surprising that certain drugs acting to block or antagonise the function of this receptor affect normal function within the brain. This may be manifested as central nervous system side effects such as hallucinations, confusion, paranoia, 5 aggression, agitation and catatonia. These side effects can be described as a psychotic state and the drugs that induce them are known as psychotomimetic NMDA antagonists. Such side effects limit the utility of these compounds in treating disease states. NMDA receptor antagonists that have efficacy in treating central nervous system disorders but without such psychotomimetic side effects would have a clear therapeutic advantage. 10 Thus, in view of the crucial role played by the NMDA receptor in either the progression or expression of the disease pathology and process, it is an object of this invention to provide compounds for the treatment of central nervous system disorders which modulate the activity of the NMDA receptor but which are well-tolerated in the sense of having a markedly reduced propensity to induce psychotomimetic side effects.

15

The present invention is particularly concerned with the treatment of neurodegenerative disorders. There is a large body of evidence to suggest that either an excitotoxic or slow excitotoxic pathological over-activation of the NMDA receptor induces the death of neurons in a variety of disorders such as ischaemic stroke, other 20 forms of hypoxic injury, haemorrhagic brain injury, traumatic brain injury, Alzheimer's disease, Parkinson's disease, Huntington's disease and other dementing diseases. There is thus clear evidence that antagonism of the NMDA receptor will reduce or prevent the neurodegeneration that underlies the disease process in these and related conditions. There is also evidence to suggest that a well tolerated compound will allow effective 25 symptomatic treatment of the manifestations of the disease process in these disorders as well as reducing the primary underlying neurodegeneration process. Also, it is known that disorders previously described as involving acute neurodegeneration have longer than expected elevations in glutamate release and consequently require longer than expected treatment with NMDA antagonists. There would therefore be a therapeutic 30 advantage for new drugs which are well tolerated and which can therefore be administered chronically.


The published literature contains references to a number of compounds and classes of compounds purported to be useful as NMDA antagonists.

The compounds Amantadine and Memantine and related anti-viral agents have
5 been known for many years.



Amantadine

10



Memantine

Patent applications have been filed directed to the use of Memantine in the treatment of Parkinson's Disease in the 1970s and as an NMDA antagonist in 1990 (see 15 EP-A-0392059 and US-A-5061703). Furthermore, International Patent application WO94/05275 proposes the use of Amantadine and related compounds such as Memantine in the treatment and prevention of non-ischaemic, long term NMDA receptor-mediated neuronal degeneration. An increase in affinity for the NMDA receptor due to substitution of the adamantine ring of Memantine with alkyl groups was noted 20 and published by Kornhuber *et al.*, Eur. J. Pharmacol., 1991, 206, 297-300, by Kroemer *et al.*, J. Med. Chem., 1998, 41, 393-400 and by Parsons *et al.*, Neuropharmacology, 1995, 34, 1239-1258.

1-(Adamantyl)amidines are disclosed as antivirals in DE-A-2306784, JP-A-7391049, DD-A-151447 and GB-1478477. 1-(Adamantyl)acetamidine is disclosed in JP-A-120683 and GB-1478477. 1-(Adamantyl)amidrazones are disclosed as insecticides and acaricides in EP-A-0604798. N-substituted-1-(adamantyl)amidines are disclosed by 5 May *et al.*, Arzneim. Forsch., 1978, 28, 732-735, and the virostatic activities of the compounds reported. N-substituted-1-(adamantyl)amidines as antivirals are disclosed by Skwarski *et al.*, Acta. Pol. Pharm., 1988, 45, 395-399.

The antiviral activities of adamantane derivatives including 1-10 (adamantyl)carbamidine and 1-(adamantyl) acetamidine are reported by Inamoto *et al.*, J. Med. Chem., 1975, 18, 713-721, where they are compared with Amantadine.

As discussed above, psychotomimetic side-effects are observed during the use of a number of well known NMDA channel blockers and therefore it will be a considerable advantage to identify clinically well-tolerated antagonists where such side effects are 15 minimised. Porter and Greenamyre (J. Neurochem. 1995, 64, 614-623; incorporated herein by reference) demonstrated that well tolerated and psychotomimetic NMDA receptor channel blockers could be differentiated on the basis of their relative affinities for forebrain and cerebellar receptors irrespective of absolute affinities. Selectivity for cerebellar NMDA receptors over forebrain NMDA receptors is observed for well-20 tolerated compounds. The basis of this observation may be related to different populations of NMDA receptor subtypes in these brain regions.

The use of a number of the known NMDA antagonists such as Dizocilpine, PCP, Cerestat and Ketamine gives rise to a number of side effects which render these 25 compounds unsuitable for use in treatment. In particular, administration of the compounds is associated with perceptual and cognitive disturbances of a kind that resemble naturally-occurring psychotic states.

In addition, the perceptual and cognitive side effects of the compounds become 30 more pronounced after the onset of puberty and sexual maturation, and these compounds are therefore particularly unsuitable for the treatment of adults. This developmental


change has been demonstrated empirically in both experimental animals and in man, and is paralleled in experimental animals by brain hypermetabolism.

In summary, there is a need for an NMDA antagonist which is well tolerated and 5 does not give rise to the side effects associated with previous clinically investigated NMDA antagonists.

A number of compounds have now been found that show affinity for the NMDA receptor and are useful in the treatment of conditions generally associated with 10 abnormalities in glutamatergic transmission such as stroke, traumatic brain injury and neurodegenerative diseases such as Parkinson's and Alzheimer's diseases. It has also been found that the compounds have a surprisingly favourable ratio of cortex to cerebellar binding affinity which indicates that these compounds should be well tolerated 15 *in vivo*.

15

According to the present invention there is provided use of a compound of the formula (1):



(1)

20 wherein X is an alkylene chain comprising 0, 1, 2, 3 or 4 carbon atoms;

R¹, R² and R³ are independently selected from hydrogen, alkyl and aryl;

R⁴, R⁵ and R⁶ are independently selected from hydrogen, alkyl, aryl, halogen and alkoxy; and prodrugs thereof and pharmaceutically acceptable salts thereof;

in the manufacture of a medicament for use in the treatment of a condition generally 25 associated with abnormalities in glutamatergic transmission.

As used herein, the term "alkyl" means a branched or unbranched, cyclic or acyclic, saturated or unsaturated (e.g. alkenyl or alkynyl) hydrocarbyl radical. Where cyclic, the alkyl group is preferably C₃ to C₁₂, more preferably C₅ to C₁₀, more preferably C₅ to C₇. Where acyclic, the alkyl group is preferably C₁ to C₁₀, more preferably C₁ to C₆, more preferably methyl, ethyl or propyl, more preferably methyl or ethyl.

As used herein, the term "aryl" means an aromatic group, such as phenyl or naphthyl, or a heteroaromatic group containing one or more, preferably one, heteratom, such as pyridyl, pyrrolyl, furanyl and thiophenyl. Preferably, the aryl group comprises phenyl.

The alkyl and aryl groups may be substituted or unsubstituted, preferably unsubstituted. Where substituted, there will generally be 1 to 3 substituents present, preferably 1 substituent. Substituents may include:-

15 carbon containing groups such as

alkyl,

aryl, arylalkyl; (e.g. substituted and unsubstituted phenyl,
substituted and unsubstituted benzyl)

halogen atoms and halogen containing groups such as

20 haloalkyl (e.g. trifluoromethyl);

oxygen containing groups such as

alcohols (e.g. hydroxy, hydroxyalkyl,

(aryl)(hydroxy)alkyl),

ethers (e.g. alkoxy, alkoxyalkyl, aryloxyalkyl),

25 aldehydes (e.g. carboxaldehyde),

ketones (e.g. alkylcarbonyl, alkylcarbonylalkyl, arylcarbonyl,
arylalkylcarbonyl, arylcarbonylalkyl)

acids (e.g. carboxy, carboxyalkyl),

acid derivatives such as esters

30 (e.g. alkoxy carbonyl, alkoxycarbonylalkyl,
alkycarbonylyoxy, alkycarbonylyoxyalkyl)

and amides

(e.g. aminocarbonyl, mono- or dialkylaminocarbonyl, aminocarbonylalkyl, mono- or dialkylaminocarbonylalkyl, arylaminocarbonyl);

5 nitrogen containing groups such as

amines (e.g. amino, mono- or dialkylamino, aminoalkyl, mono- or dialkylaminoalkyl),

azides,

nitriles (e.g. cyano, cyanoalkyl),

10 nitro;

sulphur containing groups such as

thiols, thioethers, suphoxides, and sulphones

(e.g. alkylthio, alkylsulfinyl, alkylsufonyl, alkylthioalkyl, alkylsulfinylalkyl, alkylsulfonylalkyl, arylthio, arylsulfinyl, arylsulfonyl, arylthioalkyl, arylsulfinylalkyl, arylsulfonylalkyl)

and heterocyclic groups containing one or more, preferably one, heteroatom,

(e.g. thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl, oxazolyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, tetrahydrofuranyl, pyranyl, pyronyl, pyridyl, pyrazinyl, pyridazinyl, piperidyl, piperazinyl, morpholinyl, thionaphthyl, benzofuranyl, isobenzofuryl, indolyl, oxyindolyl, isoindolyl, indazolyl, indolinyl, 7-azaindolyl, isoindazolyl, benzopyranyl, coumarinyl, isocoumarinyl, quinolyl, isoquinolyl, naphthridinyl, cinnolinyl, quinazolinyl, pyridopyridyl, benzoxazinyl, quinoxadinyl,

25

30

chromenyl, chromanyl, isochromanyl and carbolinyl).

As used herein, the term "alkoxy" means alkyl-O- and "alkoyl" means alkyl-CO-.

5

As used herein, the term "halogen" means a fluorine, chlorine, bromine or iodine radical, preferably a bromine or chlorine radical.

As used herein the term "conditions generally associated with abnormalities in glutamatergic transmission" primarily includes ischaemic stroke, haemorrhagic stroke, subarachnoid haemorrhage, subdural haematoma, coronary artery bypass surgery, neurosurgery, traumatic brain injury, traumatic spinal injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, Pick's disease, Lewy body disease, senile dementia, spongiform encephalopathies, prion-protein induced neurotoxicity, peri-natal asphyxia, demyelinating disease, multiinfarct dementia, dementia pugilans, drug dependence, alcohol withdrawal, opiate withdrawal, motor neurone disease, multiple sclerosis, acute and chronic pain including neuropathic pain, cancer pain, trigeminal neuralgia, migraine, primary and secondary hyperalgesia, inflammatory pain, nociceptive pain, tabes dorsalis, phantom limb pain, spinal cord injury pain, central pain, post-herpetic pain, HIV pain and diabetic neuropathy. In addition, the term also includes the following conditions: epilepsy, multiple system atrophy, progressive supranuclear palsy, Friedrich's ataxia, autism, fragile X syndrome, tuberous sclerosis, attention deficit disorder, olivio-ponto-cerebellar atrophy, cerebral palsy, drug-induced optic neuritis, peripheral neuropathy, myelopathy, ischaemic retinopathy, glaucoma, cardiac arrest, encephalitis, depression, bi-polar disorder, schizophrenia, psychosis, behaviour disorders, impulse control disorders, pre-eclampsia, neuroleptic malignant syndrome, chronic fatigue syndrome, anorexia nervosa, anxiety disorders, generalised anxiety disorder, panic disorder, phobias, fresh water drowning and decompression.

As used herein, the term "treatment" also includes prophylactic treatment.

As used herein, the term "pharmaceutically acceptable salt" means any pharmaceutically acceptable salt of the compound of formula (1). Salts may be prepared from pharmaceutically acceptable non-toxic acids including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, 5 dichloroacetic, ethenesulfonic, fumaric, gluconic, glutamic, hippuric, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, oxalic, p-toluenesulfonic and the like. Particularly preferred are hydrochloric, hydrobromic, phosphoric, and sulfuric acids, and most particularly preferred is the hydrochloride salt.

10 The compounds of formula (1) may exist in a number of diastereomeric and/or enantiomeric forms. Reference in the present specification to "a compound of formula (1)" is a reference to all stereoisomeric forms of the compound and includes a reference to the unseparated stereoisomers in a mixture, racemic or non-racemic, and to each stereoisomer in its pure form.

15

The compounds of the present invention are active as NMDA antagonists and are well tolerated in that side effects are minimised. Experimental data are shown in Table 1.

In the compound of formula (1), preferably X is an alkylene chain comprising 0, 1 or 2 carbon atoms, more preferably 0 carbon atoms, in the chain.

20

In one embodiment of the invention, in the compound of formula (1), where X is an alkylene chain comprising 1, 2, 3 or 4 carbon atoms, one or more of the carbon atom(s) in the chain X may be independently substituted by substituent group(s) selected from alkyl and aryl. Where substituted, a carbon atom may have one or two substituents, 25 preferably one. Preferred substituent groups are selected from methyl, ethyl, phenyl and benzyl, preferably ethyl and benzyl. Where X is substituted, it is preferred that only one carbon atom in the chain is substituted.

In an alternative embodiment of the invention, in the compound of formula (1), X is unsubstituted and has the formula $(CH_2)_n$ where n = 0 to 4, preferably n = 0, 1 or 2 and more preferably n = 0.

5 In the compound of formula (1), preferably R^1 and R^2 are hydrogen and R^3 is selected from hydrogen, alkyl and aryl. In a preferred embodiment, R^1 , R^2 and R^3 are hydrogen.

In the compound of formula (1), preferably at least one of R^4 , R^5 and R^6 is alkyl, aryl, halogen or alkoxy. Preferably R^4 is selected from hydrogen, alkyl and halogen, 10 more preferably alkyl and more preferably methyl. Preferably R^5 is selected from hydrogen and alkyl, preferably hydrogen and methyl. Preferably R^6 is selected from hydrogen and alkyl, preferably hydrogen and methyl.

In a preferred embodiment, the compound of formula (1) is a compound where X has 1 carbon atom (i.e. n = 1) and is unsubstituted; R^1 , R^2 and R^3 are hydrogen; R^4 and 15 R^5 are methyl; and R^6 is hydrogen.

In a further preferred embodiment, the compound of formula (1) is a compound where X has one carbon atom (i.e. n = 1) and is substituted by an ethyl or benzyl group; and R^1 , R^2 , R^3 , R^4 , R^5 and R^6 are hydrogen.

In a particularly preferred embodiment, the compound of formula (1) is a 20 compound of formula (1) where X has 0 carbon atoms (i.e. n = 0); R^1 , R^2 and R^3 are hydrogen; R^4 and R^5 are CH_3 ; and R^6 is hydrogen.

In a further particularly preferred embodiment, the compound of formula (1) is a compound where X has 0 carbon atoms (i.e., n = 0); R^1 , R^2 and R^3 are hydrogen; R^4 is methyl; and $R^5 = R^6 =$ hydrogen or methyl.

25 The present invention further provides a method of treatment of conditions generally associated with abnormalities in glutamatergic transmission comprising


administering to a patient an effective dose of a compound of formula (1) as defined above.

The present invention also provides a compound *per se* of the formula (1) as defined above wherein at least one of R⁴, R⁵ and R⁶ is alkyl, aryl, halogen or alkoxy, with 5 the proviso that if R¹, R² and R³ are hydrogen and R⁴, R⁵ and R⁶ are independently selected from hydrogen and C₁₋₄ alkyl, then either X is an alkylene chain of 2-4 carbon atoms, substituted or unsubstituted, as defined above, or X is an alkylene chain of 1 carbon atom substituted with one or two, preferably one, substituent group(s) independently selected from alkyl and aryl, and prodrugs and pharmaceutically 10 acceptable salts thereof.


The present invention also provides a compound *per se* of the formula (1) as defined above wherein R⁴, R⁵ and R⁶ are hydrogen and either X is an alkylene chain of 2-4 carbon atoms, substituted or unsubstituted, as defined above, or X is an alkylene 15 chain of 1 carbon atom substituted with one or two, preferably one, substituent group(s) independently selected from alkyl and aryl, or X is a CH₂ group, with the proviso that where X is a CH₂ group then at least one of R¹, R² and R³ are selected from alkyl and aryl, and prodrugs and pharmaceutically acceptable salts thereof.

20 The present invention also provides compounds *per se* of formulae (2), (3), (4) and (5):


12




(2)



(3)



(4)



(5)

and prodrugs and pharmaceutically acceptable salts thereof.

5 The present invention also provides, for use in therapy:

(i) a compound of the formula (1) as defined above wherein at least one of R⁴, R⁵ and R⁶ is alkyl, aryl, halogen or alkoxy, with the proviso that if R¹, R² and R³ are hydrogen and R⁴, R⁵ and R⁶ are independently selected from hydrogen and C₁₋₄ alkyl, then either X is an alkylene chain of 2-4 carbon atoms, substituted or unsubstituted, as defined above, or X is an alkylene chain of 1 carbon atom substituted with one or two, preferably one, substituent groups independently selected from alkyl and aryl;

10 (ii) a compound of the formula (1) as defined above wherein R⁴, R⁵ and R⁶ are hydrogen and either X is an alkylene chain of 2-4 carbon atoms, substituted or unsubstituted, as defined above, or X is an alkylene chain of 1 carbon atom substituted with one or two, preferably one, substituent groups independently selected from alkyl and aryl, or X is a

15

20

CH₂ group, with the proviso that where X is a CH₂ group then at least one of R¹, R² and R³ are selected from alkyl and aryl; and

(iii) a compound of formula (2), (3), (4) or (5) as defined above,

5

and prodrugs and pharmaceutically acceptable salts thereof.

The present invention also provides a pharmaceutical composition comprising:

10 (i) a compound of the formula (1) as defined above wherein at least one of R⁴, R⁵ and R⁶ is alkyl, aryl, halogen or alkoxy, with the proviso that if R¹, R² and R³ are hydrogen and R⁴, R⁵ and R⁶ are independently selected from hydrogen and C₁₋₄ alkyl, then either X is an alkylene chain of 2-4 carbon atoms, substituted or unsubstituted, as defined above, or X is an alkylene chain of 1 carbon atom substituted with one or two, preferably one, substituent group independently selected from alkyl and aryl; or

15 (ii) a compound of the formula (1) as defined above wherein R⁴, R⁵ and R⁶ are hydrogen and either X is an alkylene chain of 2-4 carbon atoms, substituted or unsubstituted, as defined above, or X is an alkylene chain of 1 carbon atom substituted with one or two, preferably one, substituent groups independently selected from alkyl and aryl, or X is a CH₂ group, with the proviso that where X is a CH₂ group then at least one of R¹, R² and R³ are selected from alkyl and aryl; or

20 (iii) a compound of formula (2), (3), (4) or (5) as defined above,


25 and prodrugs and pharmaceutically acceptable salts thereof, in combination with a pharmaceutically acceptable excipient.

According to a further aspect of the present invention there is provided a method of preparing the compounds of the present invention. Compounds of formula (1) may be prepared by conventional synthetic routes; see for example DD-A-151447, US-A-5061703, DE-A-2306784, GB-1478477, Skwarski et al., Acta Polon. Pharm., (1988), 45, 5 395-399 and May et al., Arzneim. Forsch., (1978), 28, 732-735, the disclosures of which are incorporated herein by reference.

The following reaction schemes describe examples of synthetic routes for the preparation of compounds falling within formula (1). The reaction schemes are included for the purpose of exemplification only and are not intended to be limiting to the invention.

Compounds of formula (1) may be synthesised by conventional synthetic methods as illustrated in Scheme 1.

Scheme 1




Amidines of formula 4 may be synthesised from nitriles of formula 3 by conventional methods, for example by treatment with an amine in the presence of trimethyl aluminium in a refluxing solvent such as toluene for several days, or alternatively by treatment with HCl in dry methanol at 0°C for several days followed by 25 treatment with NH₃ at room temperature. Nitriles of formula 3 may be synthesised from carboxylic acids of formula 2 by conventional methods, for example by treatment with methanesulphonyl chloride in the presence of pyridine, followed by treatment with NH₃,

followed by treatment with methanesulphonyl chloride in the presence of pyridine. Carboxylic acids of formula 2 are either commercially available or may be synthesised by conventional methods such as those published in Stetter *et al.*, Chem. Ber., 1962, 95, 667-672, by Koch *et al.*, Chem. Ber., 1963, 96, 213-219, by Stepanov *et al.*, Zh. Obstrich. 5 Khim., 1964, 34, 579-584, by Stepanov *et al.*, Zh. Org. Khim., 1965, 1, 280-283 and by Stepanov *et al.*, Zh. Org. Khim., 1966, 2, 1612-1615.

An alternative route for the preparation of compounds of formula (1) where X is CR⁷R⁸ wherein R⁷ and R⁸ are independently hydrogen or alkyl and wherein R¹, R², R³, 10 R⁴, R⁵ and R⁶ are as defined in formula (1), also involving conventional methods, is illustrated in Scheme 2.


Scheme 2



Amidines of formula 7 may be prepared from nitriles of formula 6 as described above. Nitriles of formula 6 may be prepared from nitriles of formula 5 by alkylation or dialkylation, for example by treatment with a base such as LDA followed by treatment 20 with an alkyl halide. Further treatment with a base followed by a second alkyl halide would give the dialkylated nitrile.

An alternative route for the preparation of compounds of formula (1) where X is CHR⁹CH₂ or CH₂CHR¹⁰ wherein R⁹ and R¹⁰ are independently alkyl or aryl and wherein 25 R¹, R², R³, R⁴, R⁵ and R⁶ are as defined above, also involving conventional methods, is illustrated in Scheme 3.


Scheme 3



Amidines of formula 11 may be prepared from nitriles of formula 10 as described 5 above. Nitriles of formula 10 may be prepared by reduction of unsaturated nitriles of formula 9, for example by hydrogenation in the presence of a transition metal catalyst such as palladium on carbon. Nitriles of formula 9 may be prepared from ketones or aldehydes of formula 8 by conventional methods such as the Horner-Emmons olefination reaction using an appropriately substituted phosphonate in the presence of a base such as 10 sodium hydride. Ketones or aldehydes of formula 8 are commercially available or may be synthesised by conventional methods.

In addition, compounds of formula (1) where X is an alkylene chain of 3 or 4 carbon atoms may be synthesised by conventional methods as illustrated in Scheme 4.

Scheme 4



5 Amidines of formula 16 and 17 may be synthesised from nitriles of formula 15 and 12 respectively by the methods described in Scheme 1. Nitriles of formula 15 may be synthesised from nitriles of formula 14 by methods described in Scheme 3 or alternatively from ketones of formula 13 by reduction to the alcohol followed by tosylation or bromination, followed by cyanide displacement. Nitriles of formula 14 may 10 be synthesised from ketones of formula 11 by methods described in Scheme 3. Ketones of formula 13 may be synthesised from nitriles of formula 12 by the addition of a Grignard reagent followed by hydrolytic work-up. Nitriles of formula 12 may be prepared from ketones of formula 11 by the reduction, tosylation/bromination and cyanide displacement sequence described above. Ketones of formula 11 may be 15 prepared from nitriles of formula 10 by Grignard reactions as described above.

Additional substituents may be introduced into the alkylene chain X by methods analogous to those described in the above schemes and by other conventional synthetic methods.

5 The compound of formula (1) may be administered in a form suitable for oral use, for example a tablet, pellet, capsule, aqueous or oily solution, suspension or emulsion; for topical use including transmucosal and transdermal use, for example a cream, ointment, gel, aqueous or oil solution or suspension, salve, patch or plaster; for nasal use, for example a snuff, nasal spray, nasal powder or nasal drops; for vaginal or
10 rectal use, for example a suppository or pessary; for administration by inhalation, for example a finely divided powder or a liquid aerosol; for sub-lingual or buccal use, for example a tablet or capsule; for ocular use, for example a sterile aqueous solution or sterile ointment; or for parenteral use (including intravenous, subcutaneous, intramuscular, intravascular or infusion), for example a sterile aqueous or oil solution or
15 suspension or emulsion, or depot injection formulation. In general the above compositions may be prepared in a conventional manner using conventional excipients, using standard techniques, including controlled release technologies, such as gelatin, lipid, gel depot, liposome and microcapsule based systems well known to those skilled in the art of pharmacy.

20 For oral administration, the compounds of the invention will generally be provided in the form of tablets or capsules or as an aqueous solution or suspension.

Tablets or pellets for oral use may include the active ingredient mixed with pharmaceutically acceptable excipients such as inert diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavouring agents, colouring agents
25 and preservatives. Suitable inert diluents include sodium and calcium carbonate, sodium and calcium phosphate, calcium hydrogen phosphate, cellulose derivatives and lactose, while corn starch and alginic acid are suitable disintegrating agents. Binding agents may include starch, gelatin and polyvinyl-pyrrolidone derivatives, while the lubricating agent, if present, will generally be magnesium stearate, stearic acid or talc. If desired, the
30 tablets may be formulated or coated with a material such as glycetyl monostearate or

glyceryl distearate or polymethacrylate polymers, cellulose derivatives or other pharmaceutically acceptable polymer, to delay absorption in the gastrointestinal tract.

Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent, and soft gelatin capsules wherein the active ingredient is 5 mixed with water or an oil such as peanut oil, liquid paraffin or olive oil.

For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions or emulsions, buffered to an appropriate pH and isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous 10 suspensions according to the invention may include suspending agents such as cellulose derivatives, sodium alginate, polyvinyl-pyrrolidone and gum tragacanth, and a wetting agent such as lecithin. Suitable preservatives for aqueous suspensions include ethyl and n-propyl p-hydroxybenzoate.

Transdermal formulations include membrane permeation systems, multi-laminate 15 adhesive dispersion systems and matrix dispersion systems. Transdermal delivery also includes the use of electrically aided transport and skin penetration enhancers and needle-free injection devices.

The preferred route of administration will be as an intravenous infusion, 20 preferably over a period of up to seven days, or as an oral formulation, or as an intramuscular injection via a styrette or as a subcutaneous injection.

It will be appreciated that the dosage levels used may vary over quite a wide range depending upon the compound used, the severity of the condition exhibited by the 25 patient and the patient's body weight. However, without commitment to a rigid definition of dosages it may be stated that a daily dosage of the active constituent (estimated as the free base) is 100 μ g to 800mg. More particularly, the preferred compounds may be administered at a preferred dose of 50-800mg/day, in single or divided doses.

The invention will now be described in detail. It will be appreciated that the invention is described by way of example only and modification of detail may be made without departing from the scope of the invention.

EXPERIMENTAL

5 I Synthesis

Example 1

3,5-Dimethyl-1-adamantanecarboximidamide hydrochloride

3,5-Dimethyl-1-adamantanecarbonitrile

A solution of 3,5-dimethyl-1-adamantanecarboxylic acid (2.51 g, 12.1 mmol) in dry 10 pyridine (40 mL) at 0 °C was treated dropwise with methanesulphonyl chloride (1.4 g, 12.2 mmol), stirred for 2 h, saturated with ammonia gas, stirred for 5 min and the excess ammonia removed *in vacuo*. The resulting suspension at 0°C was treated with methanesulphonyl chloride (11.8 g, 102 mmol), stirred overnight at room temperature, poured into cold 1-M HCl (200 mL) and extracted with EtOAc (3 x 40 mL). The organic 15 phase was washed with dilute HCl (50 mL), water (50 mL), dried (MgSO₄), concentrated *in vacuo* and the residue purified by chromatography [SiO₂; CH₂Cl₂] to give the *product* (1.97 g, 86 %) as a pale brown oil: IR ν_{max} (liquid film)/cm⁻¹ 2922, 2849, 2235, 1455, 1359 and 1098; NMR δ_{H} (400 MHz, CDCl₃) 0.87 (6H, s), 1.19 (2H, s), 1.3 - 1.45 (4H, m), 1.55 - 1.75 (4H, m), 1.8 - 1.9 (2H, m) and 2.1 - 2.15 (1H, m).

20 *3,5-Dimethyl-1-adamantanecarboximidamide hydrochloride*

A solution of 3,5-dimethyl-1-adamantanecarbonitrile (1.95 g, 10.3 mmol) in MeOH (30 mL) at 0 °C was saturated with HCl gas over 30 min, left at 0 °C for 5 days, concentrated *in vacuo*, the residue triturated with EtOAc and filtered to give the intermediate imide hydrochloride salt (1.16g, 44 %) as a hygroscopic solid. The solid (302 mg, 1.17 mmol) 25 in MeOH (20 mL) at 0 °C was saturated with ammonia gas, left at room temperature for 4 days, concentrated to a small volume *in vacuo*, treated with EtOAc and filtered to give the *title compound* (240 mg, 85 %) as a white crystalline solid: mp 297-229 °C; IR ν_{max}

(Nujol)/cm⁻¹ 3166, 1673, 1508, 1087 and 729; NMR δ_H (400 MHz, DMSO-*d*₆) 0.85 (6H, s), 1.20 - 1.50 (2H, m), 1.30 - 1.40 (4H, m), 1.40 - 1.60 (4H, m), 1.69 (2H, m), 2.12 (2H, m), 8.55 (2H, br s) and 8.90 (2H, br s); Anal. Calcd for C₁₃H₂₃N₂Cl · 0.1 H₂O: C, 63.84; H, 9.56; N, 11.45. Found: C, 63.73; H, 9.34; N, 11.46.

5 Example 2

3-Chloro-1-adamantanecarboximidamide hydrochloride

3-Chloro-1-adamantanecarbonitrile

This was prepared from 3-chloro-1-adamantanecarboxylic acid by the method of example 1 and the *product* isolated (2.12g, 94 %) as a pale brown solid: mp 156-157 °C; 10 IR ν_{max} (Nujol)/cm⁻¹ 2249, 2230, 1248, 1124, 972 and 734; NMR δ_H (400 MHz, CDCl₃) 1.64 - 1.73 (2H, m), 1.96 - 2.04 (4H, m), 2.07 - 2.16 (4H, m), 2.25 - 2.30 (2H, m) and 2.38 (2H, s); Anal. Calcd for C₁₁H₁₄NCl: C, 67.52; H, 7.21; N, 7.15. Found: C, 67.52; H, 7.18; N, 6.94.

3-Chloro-1-adamantanecarboximidamide hydrochloride

15 This was prepared from 3-chloro-1-adamantanecarbonitrile by the method of example 1 and the *title compound* isolated (272 mg, 96 %) as a white crystalline solid: mp 215-216 °C; IR ν_{max} (Nujol)/cm⁻¹ 3455, 3376, 3306, 3148, 1687, 1667, 1082, 837, 733 and 701; NMR δ_H (400 MHz, DMSO-*d*₆) 1.55 - 1.65 (2H, m), 1.80 - 1.90 (4H, m), 2.05 - 2.15 (4H, m), 2.25 (2H, s), 2.28 (2H, s), 8.70 (2H, s) and 9.04 (2H, s); Anal. Calcd for 20 C₁₁H₁₈N₂Cl₂ · H₂O · 0.1 NH₄Cl: C, 48.48; H, 7.54; N, 10.79. Found: C, 48.81; H, 7.63; N, 10.86.

Example 3

3-Bromo-1-adamantanecarboximidamide hydrochloride

25

This was prepared from 3-bromo-1-adamantanecarbonitrile by the method of example 1 and the *title compound* isolated (276 mg, 97 %) as a white crystalline solid: mp 221-223 °C; IR ν_{max} (Nujol)/cm⁻¹ 3453, 3373, 3307, 3152, 1687, 1667, 1081, 825, 722, 699 and 679; NMR δ_H (400 MHz, DMSO-*d*₆) 1.60 - 1.70 (2H, m), 1.85 - 1.95 (4H, m), 2.21 (2H,

s), 2.25 - 2.35 (4H, m), 2.50 (2H, s) and 8.8 (4H, br s); Anal. Calcd for $C_{11}H_{18}N_2BrCl \cdot H_2O$: C, 42.39; H, 6.47; N, 8.99. Found: C, 42.17; H, 6.48; N, 9.08.

Example 4

5 3-Ethyl-1-adamantanecarboximidamide hydrochloride

This was prepared from 3-ethyl-1-adamantanecarbonitrile by the method of example 1 and the *title compound* isolated (1.74 g, 94 %) as a white crystalline solid: mp 210-212 °C; IR ν_{max} (Nujol)/cm⁻¹ 3266, 3070, 1665, 1089 and 734; NMR δ_H (400 MHz, DMSO-¹⁰ d_6) 0.79 (3H, t, *J* 7.75 Hz), 1.1 - 1.2 (2H, m), 1.35 - 1.45 (4H, m), 1.5 - 1.65 (4H, m), 1.7 - 1.85 (2H, m), 2.09 (2H, s), 8.56 (2H, br s) and 8.92 (2H, br s); Anal. Calcd for $C_{13}H_{23}N_2Cl$: C, 64.31; H, 9.55; N, 11.53. Found: C, 64.05; H, 9.95; N, 11.49.

Example 5**3,5-Dimethyl-1-adamantaneacetimidamide hydrochloride***3,5-Dimethyl-1-adamantaneacetonitrile*

5

This was prepared from 3,5-dimethyl-1-adamantaneacetic acid (Bott and Hellman, Angew. Chem. Int. Ed. Engl., 1966, 5,870, the disclosure of which is incorporated herein by reference) by the method of example 1 and the *product* isolated (833 mg, 88 %) as a pale brown oil: IR ν_{max} (liquid film)/cm⁻¹ 2900, 2843, 2244, 1455, 1360 and 1345; NMR 10 δ_{H} (400 MHz, CDCl₃) 0.84 (6H, s), 1.1 - 1.3 (6H, m), 1.32 - 1.35 (2H, m), 1.44 - 1.47 (2H, m), 2.12 (2H, s) and 2.05 - 2.15 (1H, m).

3,5-Dimethyl-1-adamantaneacetimidamide hydrochloride

This was prepared from 3,5-dimethyl-1-adamantaneacetonitrile by the method of example 1 and the *title compound* isolated (778 mg, 100 %) as a white crystalline solid: 15 mp 252-253 °C; IR ν_{max} (Nujol)/cm⁻¹ 3384, 3076, 1691 and 722; NMR δ_{H} (400 MHz, DMSO-d₆) 0.81 (6H, s), 1.0 - 1.25 (6H, m), 1.25 - 1.35 (4H, m), 1.38 (2H, s), 2.04 (1H, m), 2.17 (2H, s) and 8.76 (4H, br s); Anal. Calcd for C₁₄H₂₅N₂Cl · 0.9 H₂O: C, 61.59; H, 9.89; N, 10.26. Found: C, 61.69; H, 10.31; N, 10.19.

Example 6**20 N-Allyl-3,5-dimethyl-1-adamantanecarboximidamide hydrochloride**

This was prepared from 3,5-dimethyl-1-adamantanecarbonitrile by the method of example 1 using allylamine (3 eq) instead of ammonia. The *title compound* was isolated (46 mg, 42 %) as a white crystalline solid: mp 222-224 °C; IR ν_{max} (Nujol)/cm⁻¹ 3039, 1671, 1614, 993, 932, 810 and 722; NMR δ_{H} (400 MHz, DMSO-d₆) 0.85 (6H, s), 1.16 - 25 1.19 (2H, m), 1.3 - 1.4 (4H, m), 1.48 - 1.6 (4H, m), 1.75 (2H, m), 2.14 (1H, m), 3.92 (2H, m), 5.10 - 5.20 (2H, m), 5.75 - 5.85 (1H, m), 8.7 (2H, br s) and 9.0 (1H, br s); Anal. Calcd for C₁₆H₂₇N₂Cl · 0.2 H₂O: C, 67.09; H, 9.64; N, 9.78. Found: C, 67.09; H, 9.56; N, 9.53.

Example 7**N-Allyl-1-adamantanecarboximidamide hydrochloride**

This was prepared from 1-adamantanecarbonitrile by the method of example 1 using 5 allylamine (3 eq) instead of ammonia. The *title compound* was isolated (298 mg, 90 %) as a white crystalline solid: mp 252-254 °C; IR ν_{max} (Nujol)/cm⁻¹ 3185, 3031, 1678, 1613, 1257, 799, 751 and 717; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.65 - 1.70 (6H, m), 1.9 - 2.0 (6H, m), 2.04 (3H, s), 3.95 (2H, m), 5.1 - 5.2 (2H, m), 5.75 - 5.85 (1H, m), 8.71 (1H, s), 8.79 (1H, s) and 9.15 (1H, s); Anal. Calcd for C₁₄H₂₃N₂Cl: C, 65.99; H, 9.10; N, 10 10.99. Found: C, 65.92; H, 9.04; N, 11.05.

Example 8**N-Ethyl-1-adamantanecarboximidamide hydrochloride**

This was prepared from 1-adamantanecarbonitrile by the method of example 1 using 2-M ethylamine in MeOH (3 eq) in place of ammonia and the *title compound* isolated (175 15 mg, 55 %) as a white crystalline solid: mp 315 °C (dec); IR ν_{max} (Nujol)/cm⁻¹ 3191, 3030, 1682, 1616, 1354, 810 and 766; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.10 (3H, t, *J* 7.0 Hz), 1.6 - 1.7 (6H, m), 1.85 - 1.90 (6H, m), 2.0 - 2.05 (3H, m), 3.30 (2H, pent, *J* 7.0 Hz), 8.67 (1H, s), 8.71 (1H, s) and 8.86 (1H, s); Anal. Calcd for C₁₃H₂₃N₂Cl: C, 64.31; H, 9.55; N, 11.54. Found: C, 64.27; H, 9.56; N, 11.54.

20 Example 9**N-Benzyl-1-adamantanecarboximidamide hydrochloride**

This was prepared from 1-adamantanecarbonitrile by the method of example 1 using benzylamine (1.1 eq) in place of ammonia and the *title compound* isolated (357 mg, 90 %) as a white crystalline solid: mp 242-244 °C; IR ν_{max} (Nujol)/cm⁻¹ 3049, 1677, 1605, 25 1240, 759, 728 and 703; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.65 - 1.70 (6H, m), 1.9 - 2.0 (6H, m), 2.05 (3H, s), 4.58 (2H, s), 7.3 - 7.4 (5H, m), 8.80 (1H, s), 8.85 (1H, s) and 9.55 (1H, s); Anal. Calcd for C₁₈H₂₅N₂Cl: C, 70.92 ; H, 8.27; N, 9.18. Found: C, 70.62; H, 8.21; N, 9.18.

Example 10**N-(2-Dimethylaminoethyl)-1-adamantanecarboximidamide dihydrochloride**

This was prepared from 1-adamantanecarbonitrile by the method of example 1 using N,N-dimethylethylenediamine (3 eq) in place of ammonia and the *title compound* 5 isolated (42 mg, 10 %) as a white crystalline solid: mp 293 °C (dec); IR ν_{max} (Nujol)/cm⁻¹ 3192, 2581, 2469, 1697, 1605 and 798; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.65 - 1.75 (6H, m), 1.94 (6H, s), 2.04 (3H, s), 2.81 (6H, s), 3.27 (2H, m), 3.72 (2H, m), 8.98 (1H, s), 9.04 (1H, s), 9.13 (1H, s) and 10.86 (1H, s); Anal. Calcd for C₁₅H₂₉N₃Cl₂ · 0.25 H₂O: C, 55.12; H, 9.10; N, 12.86. Found: C, 55.23; H, 9.00; N, 12.89.

10 Example 11**3-(3,5-Dimethyl-1-adamantyl)propanimidamide hydrochloride****3-(3,5-Dimethyl-1-adamantyl)propionitrile**

A solution of 1-bromo-3,5-dimethyladamantane (1.0 g, 4.11 mmol), acrylonitrile (436 mg, 8.22 mmol) and 1,1'-azobis(cyclohexanecarbonitrile) (50 mg, 0.21 mmol) in dry 15 toluene (12 mL) was treated with tri-*n*-butyltin hydride (1.44 g, 4.93 mmol) at room temperature, refluxed for 3.5 h, cooled, diluted with ether (30 mL), washed with 0.2-M NH₄OH (30 mL), water (10 mL), dried (MgSO₄) and concentrated *in vacuo*. The residue was purified by chromatography [SiO₂, CH₂Cl₂-hexane (0:100 to 100:0)] to give the product (771 mg, 86 %) as a colourless oil: IR ν_{max} (liquid film)/cm⁻¹ 2899, 2841, 2247, 20 1545 and 1359; NMR δ_{H} (400 MHz, CDCl₃) 0.81 (6H, s), 1.0 - 1.2 (6H, m), 1.25 - 1.35 (6H, m), 1.53 (2H, t, *J* 4.2 Hz), 2.05 - 2.10 (1H, m) and 2.27 (2H, t, *J* 4.2 Hz).

3-(3,5-Dimethyl-1-adamantyl)propanimidamide hydrochloride

This was prepared from 3-(3,5-dimethyl-1-adamantyl)propionitrile by the method of example 1 and the *title compound* isolated (609 mg, 86 %) as a white crystalline solid: 25 mp 246-248 °C; IR ν_{max} (Nujol)/cm⁻¹ 3076, 1681, 789 and 749; NMR δ_{H} (400 MHz, DMSO-*d*₆) 0.80 (6H, s), 1.08 (6H, q, *J* 12.5 Hz), 1.28 (6H, d *J* 2.6 Hz), 1.39 (2H, m), 2.02 (1H, m), 2.31 (2H, m), 8.65 (2H, br s) and 8.99 (2H, br s); Anal. Calcd for C₁₅H₂₅N₂Cl · 0.2 NH₄Cl: C, 63.99; H, 9.95; N, 10.95. Found: C, 64.15; H, 9.98; N, 10.87.

Example 12**3-Methyl-1-adamantanecarboximidamide hydrochloride****5 3-Methyl-1-adamantanecarbonitrile**

This was prepared from 3-methyl-1-adamantanecarboxylic acid by the method of example 1 and the *product* (1.81 g, 80 %) isolated as a pale brown waxy solid: IR ν_{max} (Nujol)/cm⁻¹ 2923, 2853, 2233, 1456, 1377, 1360, 1343, 1161 and 1111; NMR δ_{H} (400 MHz, CDCl₃) 0.85 (3H, s), 1.45 (4H, m), 1.63 (2H, m), 1.74 (2H, s), 1.94 (4H, m) and 2.07 (2H, m).

3-Methyl-1-adamantanecarboximidamide hydrochloride

This was prepared from 3-methyl-1-adamantanecarbonitrile by the method of example 1 and the *title compound* (1.26 g, 95 %) isolated as a white crystalline solid: mp 255 – 257 °C; IR ν_{max} (Nujol)/cm⁻¹ 3222, 3084, 2923, 2853, 1674, 1502, 1456, 1376, 1087 and 737; NMR δ_{H} (400 MHz, DMSO-*d*₆) 0.83 (3H, s), 1.42 (4H, m), 1.58 (4H, m), 1.77 (4H, m), 2.07 (2H, m), 8.61 (2H, br s) and 8.99 (2H, br s); NMR δ_{C} (100 MHz, DMSO-*d*₆) 28.1, 30.2, 30.8, 34.9, 37.5, 42.7, 44.6 and 177.0.

20 Example 13**3,5,7-Trimethyl-1-adamantanecarboximidamide hydrochloride****3,5,7-Trimethyl-1-adamantanecarbonitrile**

This was prepared from 3,5,7-trimethyl-1-adamantanecarboxylic acid by the method of example 1 and the *product* (2.01 g, 88 %) isolated as a waxy solid: IR ν_{max} (Nujol)/cm⁻¹ 2923, 2864, 2230, 1456, 1377, 1358, 1350, 1257, 1095 and 912; NMR δ_{H} (400 MHz, CDCl₃) 0.90 (9H, s), 1.12 (6H, m) and 1.60 (6H, s).

3,5,7-Trimethyl-1-adamantanecarboximidamide hydrochloride

This was prepared from 3,5,7-trimethyl-1-adamantanecarbonitrile by the method of example 1 and the *title compound* (0.98 g, 98 %) isolated as a white crystalline solid:

mp 325 °C; IR ν_{max} (Nujol)/cm⁻¹ 3266, 3094, 2923, 2854, 1666, 1517, 1454, 1376, 1365, 1113, 1098 and 741; NMR δ_{H} (400 MHz, DMSO-*d*₆) 0.86 (9H, s), 1.09 (6H, m), 1.44 (6H, s), 8.59 (2H, br s) and 8.99 (2H, br s); NMR δ_{C} (100 MHz, DMSO-*d*₆) 30.0, 31.8, 40.9, 43.5, 49.2 and 176.7.

5

Example 14

3-(4-Nitrophenyl)-1-adamantanecarboximidamide hydrochloride

3-(4-Nitrophenyl)-1-adamantanecarbonitrile

10 This was prepared from 3-(4-nitrophenyl)-1-adamantanecarboxylic acid by the method of example 1 and the *product* (0.92 g, 93 %) isolated as a pale brown solid: IR ν_{max} (Nujol)/cm⁻¹ 2923, 2854, 2235, 1594, 1516, 1458, 1377, 1353, 1111 and 858; NMR δ_{H} (400 MHz, CDCl₃) 1.79 (2H, m), 1.94 (4H, m), 2.11 (4H, m), 2.21 (2H, s), 2.30 (2H, m), 7.49 (2H, m) and 8.20 (2H, m).

15

3-(4-Nitrophenyl)-1-adamantanecarboximidamide hydrochloride

This was prepared from 3-(4-nitrophenyl)-1-adamantanecarbonitrile by the method of example 1 and the *title compound* (0.22 g, 77 %) isolated as a white crystalline solid: mp 256 – 259 °C; IR ν_{max} (Nujol)/cm⁻¹ 3448, 3365, 3314, 3160, 3074, 2923, 2854, 1686, 1664, 1608, 1596, 1512, 1455, 1377, 1351, 741 and 697; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.72 (2H, m), 1.93 (8H, m), 2.09 (2H, s), 2.25 (2H, m), 7.75 (2H, m), 8.21 (2H, m), 8.73 (2H, br s) and 8.93 (2H, br s).

Example 15

2-(1-Adamantyl)butanimidamide hydrochloride

2-(1-Adamantyl)butanenitrile

A solution of diisopropylamine (0.45 mL, 3.2 mmol) in dry THF (15 mL) at -78 °C was treated with n-BuLi (1.6-M, 2 mL, 3.2 mmol), stirred at -78 °C for 15 min, 30 treated with a solution of 2-(1-adamantyl)acetonitrile (0.5 g, 2.9 mmol) in dry THF (5 mL) and stirred at -78 °C for 1 h. Ethyl iodide (0.26 mL, 3.2 mmol) was added

dropwise, the solution stirred at -78 °C for 2 h, allowed to warm to room temperature, treated with NH₄Cl solution (20 mL), extracted with EtOAc (3 x 10 mL), the extracts washed with brine (10 mL), dried (MgSO₄) and concentrated *in vacuo* to give the *product* (0.56 g, 97 %) as a pale brown solid: mp 53 – 54 °C; IR ν_{max} (Nujol)/cm⁻¹ 5 2914, 2231, 1455, 1378, 1366, 1346, 1317, 1091 and 979; NMR δ_{H} (400 MHz, CDCl₃) 1.11 (3H, t, *J* 7.4 Hz), 1.49 (1H, m), 1.74 – 1.64 (13H, m) and 2.06 (4H, m); Anal. Calcd for C₁₄H₂₁N · 0.1 H₂O: C, 81.97; H, 10.42; N, 6.83. Found: C, 81.92; H, 10.68; N, 6.74.

10 *2-(1-Adamantyl)butanimidamide hydrochloride*

A suspension of NH₄Cl (1.38 g, 26 mmol) in dry toluene (8 mL) at 0 °C was treated dropwise with 2-M trimethylaluminium in toluene (13 mL, 26 mmol), allowed to warm to room temperature and stirred for 2 h. This solution was added to a solution of 2-(1-adamantyl)butanenitrile (0.44 g, 2.2 mmol) in dry toluene (10 mL) and the 15 resulting solution refluxed for 4 days, cooled to room temperature and poured into a slurry of SiO₂ (5 g) and CHCl₃ (10 mL). The slurry was filtered, the filtrate treated with Na₂SO₄, concentrated *in vacuo* and the residue loaded on to the top of a silica column and purified by chromatography [SiO₂; EtOAc-MeOH (9:1 to 4:1)] to give the *title compound* (0.38 g, 68 %) as a white solid: mp 223 °C (dec); IR ν_{max} (Nujol)/cm⁻¹ 20 3332, 3157, 3071, 2925, 2852, 1666, 1510, 1462, 1377 and 724; NMR δ_{H} (400 MHz, DMSO-*d*₆) 0.81 (3H, t, *J* 7.2 Hz), 1.39 (2H, m), 1.56 – 1.69 (11H, br m), 1.96 (3H, m), 2.13 (1H, m) and 9.08 (4H, br m); NMR δ_{C} (100 MHz, DMSO-*d*₆) 11.8, 17.0, 27.8, 34.1, 36.2, 39.5, 56.0 and 171.0.

25 **Example 16**

2-(1-Adamantyl)-3-phenylpropanimidamide hydrochloride

This was prepared from 2-(1-adamantyl)-2-phenylpropanenitrile by the method of example 15 and the *title compound* (0.11 g, 46 %) isolated as a white crystalline solid: 30 mp 147 – 148 °C; IR ν_{max} (Nujol)/cm⁻¹ 3250 br, 2923, 2852, 1679, 1495, 1456, 1377, 1346, 1313, 1084, 739 and 699; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.51 (3H, m), 1.66

(6H, m), 1.79 (3H, m), 2.01 (3H, m), 2.60 (1H, m), 2.96 (2H, m), 7.24 (5H, m), 8.60 (1H, br s), 8.78 (1H, br s), 8.92 (1H, br s) and 9.05 (1H, br s).

Example 17**5 3-(1-Adamantyl)-2-phenylpropanimidamide hydrochloride*****3-(1-Adamantyl)-2-phenylpropanenitrile***

A solution of diethyl 1-cyano-1-phenylmethylphosphonate (10.97 g, 43.3 mmol) in dry THF (60 mL) at 0 °C was treated with NaH (60 % dispersion in oil, 1.7 g, 43.3 mmol), stirred at 0 °C for 40 min, warmed to room temperature for 20 min, treated with a solution of 1-adamantanecarboxaldehyde (3.56 g, 21.7 mmol) in dry THF (10 mL) and heated at 60 °C for 16 h. The reaction mixture was cooled, treated with water (50 mL), extracted with EtOAc (3 x 20 mL), the extracts washed with brine (40 mL), dried (MgSO₄) and concentrated *in vacuo*. The resulting brown oil was purified by chromatography [SiO₂, heptane-EtOAc (9:1)] and recrystallised (heptane) to give the product (1.62 g, 28 %) as a white solid: mp 107 – 108 °C; IR ν_{max} (Nujol)/cm⁻¹ 2924, 2852, 2218, 1497, 1448, 1377, 1343, 1101, 910, 762, 750 and 689; NMR δ_{H} (400 MHz, CDCl₃) 1.76 (6H, m), 1.99 (6H, m), 2.07 (3H, m), 6.50 (1H, s), 7.37 (3H, m) and 7.51 (2H, m); Anal. Calcd for C₁₉H₂₁N: C, 86.65; H, 8.04; N, 5.32. Found: C, 86.58; H, 8.09; N, 5.33.

3-(1-Adamantyl)-2-phenylpropanenitrile

A solution of 3-(1-adamantyl)-2-phenylpropanenitrile (600 mg, 2.28 mmol) in EtOAc (30 mL) was treated with 10 % Pd/C (70 mg), hydrogenated at 50 psi for 16 h, filtered through SiO₂ and concentrated *in vacuo*. The residue was purified by chromatography [SiO₂, EtOAc-heptane (1:1)] and the resulting solid recrystallised (heptane) to give the product (552 mg, 91 %) as a white crystalline solid: mp 83 – 84 °C; IR ν_{max} (Nujol)/cm⁻¹ 2912, 2852, 2239, 1497, 1453, 1377, 1355, 1346, 1105, 749, 713 and 696; NMR δ_{H} (400 MHz, CDCl₃) 1.50 (1H, dd, *J* 14.3, 3.2 Hz), 1.63 (9H, m), 1.72 (3H, m), 1.94 (1H, dd, *J* 14.3, 10.4 Hz), 2.01 (3H, m), 3.79 (1H, dd, *J* 10.4, 3.2 Hz) and

7.35 (5H, m); Anal. Calcd for C₁₉H₂₃N: C, 85.99; H, 8.73; N, 5.28. Found: C, 85.96; H, 8.90; N, 5.27.

3-(1-Adamantyl)-2-phenylpropanimidamide hydrochloride

5 This was prepared from 3-(1-adamantyl)-2-phenylpropanenitrile by the method of example 15 and the *title compound* (92 mg, 60 %) isolated as a pale brown solid: mp 253 °C (dec); IR ν_{max} (Nujol)/cm⁻¹ 3243, 2918, 2853, 1680, 1496, 1455, 1377, 1105, 1080, 754, 721 and 705; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.40 (3H, m), 1.55 (7H, m), 1.68 (3H, m), 1.92 (3H, m), 2.15 (1H, m), 4.05 (1H, m), 7.31 (1H, m), 7.40 (2H, m), 10 7.52 (2H, m) and 9.01 (4H, br s).

Example 18

3-(1-Adamantyl)-3-phenylpropanimidamide hydrochloride

15 This was prepared from 3-(1-adamantyl)-3-phenylpropanenitrile by the method of example 15 and the *title compound* (130 mg, 50 %) isolated as a pale yellow solid: mp 249 °C (dec); IR ν_{max} (Nujol)/cm⁻¹ 3400 – 2800 br, 2957, 1684, 1455, 1407, 1377, 772 and 704; NMR δ_{H} (400 MHz, DMSO-*d*₆) 1.37 (3H, m), 1.51 (6H, m), 1.60 (3H, m), 1.92 (3H, m), 2.91 (3H, m), 7.25 (5H, m), 8.50 (2H, br s) and 9.00 (2H, br s).

20

II NMDA Receptor Binding

The NMDA receptor contains several distinct binding domains that can regulate opening of the cationic channel. The phencyclidine (PCP) site of the NMDA receptor can 25 be radiolabeled with [³H]-(+)-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine hydrogen maleate, [³H-MK-801]. The following describes the procedure for determining the affinity of compounds for the PCP site in rat cortical or cerebellar membranes.

30 Frozen rat cortex or cerebellum, homogenized in 10 volumes of ice cold 0.32 M. sucrose is centrifuged at 1,000 g for 12 min and the supernatant stored on ice whilst the

pellet was resuspended, rehomogenized and recentrifuged twice more. The three final supernatants were pooled and centrifuged at 30,000 g for 40 min at 4°C to yield P₂ pellets. These were resuspended in ice-cold distilled water, and centrifuged at 30,000 g for 50 min at 4°C. Following three further washes in distilled water, the P₂ pellets were 5 stored at -20°C for at least 18h. On the day of the assay, membrane pellets were thawed at room temperature, resuspended in ice-cold distilled water and centrifuged at 30,000 g for 20 min. The pellets were resuspended in 50 mM tris-HCl (pH:7.4) and recentrifuged twice more before being resuspended in tris-HCl for immediate use in the assay. Binding assays were performed at equilibrium in a total volume of 200 µl, containing, [³H]-MK-
10 801 (5 nM final conc.), 10 µM glutamate, 10 µM glycine, 160 µl of membrane preparation and additional drugs where appropriate. Non-specific binding was determined using MK-801 (10 µM). The assay was incubated for 120 min at room temperature. The incubation was terminated by rapid filtration through Whatman GF/B filters (pre-soaked in 0.1% PEI solution). The assay tubes and filters were washed five 15 times with 1ml of ice cold assay buffer. The filters were placed in poly-Q mini vials with approximately 5ml of scintillation fluid. The vials are then shaken and left for at least 8 hours before being counted on a liquid scintillation counter. To determine the free ligand concentration 3 aliquots (20µl) of the [³H]-MK-801 working solution were also counted. Concentration response data for drugs was analysed using a 4 parameter equation fitted 20 by non linear regression. This yielded the half maximally effective drug concentration (IC₅₀) and Hill coefficient.


The data obtained from these assays are presented in Table 1. The data clearly demonstrate that the compounds of the invention are active as NMDA antagonists and 25 have favourable ratios of cortical to cerebellar binding affinity indicating that the compounds will be well-tolerated *in vivo*.

Table 1. Binding Affinities at Cortical and Cerebellar NMDA Receptors

Compound	IC ₅₀ (μM) Cortex	IC ₅₀ (μM) Cerebellum	Ratio
Example 1	28	6	4.7
Example 2	291		
Example 3	188	105	1.8
Example 4	122	56	2.2
Example 5	82	56	1.5
Example 6	31		
Example 7	698	297	2.4
Example 8	1000		
Example 9	754	388	1.9
Example 10	1000		
Example 11	78	48	1.6
Example 12	96	36	2.7
Example 13	43	18	2.4
Example 14	406	234	1.7
Example 15	144	46	3.1
Example 16	52	27	1.9
Example 17	16		
Example 18	27		

CLAIMS

1. Use of a compound of the formula (1):



(1)

5

wherein X is an alkylene chain comprising 0, 1, 2, 3 or 4 carbon atoms;
 R¹, R² and R³ are independently selected from hydrogen, alkyl and aryl;
 R⁴, R⁵ and R⁶ are independently selected from hydrogen, alkyl, aryl, halogen and alkoxy;
 and prodrugs thereof and pharmaceutically acceptable salts thereof;

10 in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission.

2. Use of a compound according to claim 1 wherein X is an alkylene chain comprising 1, 2, 3 or 4 carbon atoms and one or more carbon atom(s) of the chain X is/are 15 independently substituted by substituent group(s) selected from alkyl and aryl.

3. Use of a compound according to claim 2 wherein a substituted carbon atom is substituted by one substituent group selected from alkyl and aryl.

20 4. Use of a compound according to claim 2 wherein a substituted carbon atom is substituted by two substituent groups independently selected from alkyl and aryl.

5. Use of a compound according to claim 2, 3 or 4 wherein the substituent group(s) are selected from methyl, ethyl, phenyl and benzyl.

6. Use of a compound according to claim 2, 3, 4 or 5 wherein one carbon atom of the chain X is substituted.

5 7. Use of a compound according to claim 1 wherein X is $(CH_2)_n$ where n = 0 to 4.

8. Use of a compound according to any one of claims 1 to 7 wherein X is an alkylene chain comprising 1 or 2 carbon atoms in the chain.

10 9. Use of a compound according to claim 7 wherein n = 0.

10. Use of a compound according to any preceding claim wherein R¹ and R² are hydrogen and R³ is selected from hydrogen, alkyl and aryl.

15 11. Use of a compound according to any preceding claim wherein R¹, R² and R³ are hydrogen.

12. Use of a compound according to any one of claims 1 to 11 wherein at least one of R⁴, R⁵ and R⁶ is alkyl, aryl, halogen or alkoxy.

20

13. Use of a compound according to any one of claims 1 to 12 wherein R⁴ is selected from hydrogen, alkyl and halogen.

14. Use of a compound according to any one of claims 1 to 13 wherein R⁵ is selected 25 from hydrogen and alkyl.

15. Use of a compound according to any one of claims 1 to 14 wherein R⁶ is selected from hydrogen and alkyl.

30 16. Use of a compound according to claim 1 wherein X has 0 carbon atoms; R¹, R² and R³ are hydrogen; R⁴ and R⁵ are CH₃; and R⁶ is hydrogen.

17. Use of a compound according to claim 1 wherein X has 0 carbon atoms; R¹, R² and R³ are hydrogen; R⁴ is methyl; and R⁵ = R⁶ = hydrogen or methyl

5 18. Use of a compound according to claim 2 wherein X has one carbon atom and is substituted by an ethyl or benzyl group; and R¹, R², R³, R⁴, R⁵ and R⁶ are hydrogen.


19 Use of a compound according to claim 1 wherein X has one carbon atom and is unsubstituted; R¹, R² and R³ are hydrogen; R⁴ and R⁵ are methyl and R⁶ is hydrogen.

10


20. A compound of formula (1) as defined in any of claims 1 to 19 wherein at least one of R⁴, R⁵ and R⁶ is alkyl, aryl, halogen or alkoxy, with the proviso that if R¹, R² and R³ are hydrogen and R⁴, R⁵ and R⁶ are independently selected from hydrogen and C₁₋₄ alkyl, then either X is an alkylene chain comprising 2, 3 or 4 carbon atoms, substituted or 15 unsubstituted, or X is an alkylene chain of one carbon atom substituted with one or two substituent group(s) independently selected from alkyl and aryl, and prodrugs and pharmaceutically acceptable salts thereof.

21. A compound of formula (1) as defined in any of claims 1 to 19 wherein R⁴, R⁵ and 20 R⁶ are hydrogen and either X is an alkylene chain of 2, 3, or 4 carbon atoms, substituted or unsubstituted, or X is an alkylene chain of 1 carbon atom substituted with one or two substituent group(s) independently selected from alkyl and aryl, or X is a CH₂ group, with the proviso that where X is a CH₂ group then at least one of R¹, R² and R³ are selected from alkyl and aryl, and prodrugs and pharmaceutically 25 acceptable salts thereof.


22. A compound of formula (2), (3), (4) or (5):




(2)



(3)



(4)



(5)

and prodrugs and pharmaceutically acceptable salts thereof.

5 23. A compound according to any one of claims 20 to 22 for use in therapy.

24. A pharmaceutical composition comprising a compound according to any one of claims 20 to 22 in combination with a pharmaceutically acceptable excipient.

10 25. A method of treatment of a condition generally associated with abnormalities in glutamatergic transmission comprising administration to a patient in need of such treatment of a pharmaceutically effective dose of a compound of formula (1) as defined in any one of claims 1 to 19.

INTERNATIONAL SEARCH REPORT

Int'l Application No
PCT/GB 98/03715

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C07C257/16 C07C257/14

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07C

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	GB 1 478 477 A (KAO SOAP CO. LTD.) 29 June 1977 cited in the application see claim 1 ----	22
A	DD 151 447 A (HUMBOLDT-UNIVERSITÄT ZU BERLIN) 21 October 1981 cited in the application see page 13 ----	21
A	DE 23 06 784 A (SANDOZ AG) 30 August 1973 cited in the application see claims 2,3 ----	1,21,22
A	US 5 552 443 A (J.F.W. KEANA ET AL) 3 September 1996 see claim 4 ----	21,22

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

22 March 1999

Date of mailing of the international search report

29/03/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Kapteyn, H

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 98/03715

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
GB 1478477	A 29-06-1977	JP 917433	C	15-08-1978	
		JP 50064254	A	31-05-1975	
		JP 52046949	B	29-11-1977	
		CH 594612	A	13-01-1978	
		DE 2449840	A	24-04-1975	
		US 3906044	A	16-09-1975	
DD 151447	A 21-10-1981	NONE			
DE 2306784	A 30-08-1973	CH 560678	A	15-04-1975	
		AU 5217473	A	15-08-1974	
		BE 795381	A	13-08-1973	
		DD 105213	A	12-04-1974	
		FR 2181731	A	07-12-1973	
		JP 48091049	A	27-11-1973	
		NL 7301841	A	17-08-1973	
US 5552443	A 03-09-1996	US 5308869	A	03-05-1994	
		AU 671071	B	15-08-1996	
		AU 8548191	A	30-03-1992	
		CA 2089261	A	01-03-1992	
		EP 0551330	A	21-07-1993	
		JP 6501002	T	27-01-1994	
		WO 9204054	A	19-03-1994	